» Articles » PMID: 28660166

Neuroleptic Malignant Syndrome in the Trauma Intensive Care Unit: Diagnosis and Management of a Rare Disease in a Challenging Population

Overview
Specialty Critical Care
Date 2017 Jun 30
PMID 28660166
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroleptic malignant syndrome (NMS) is a life-threatening neurological disorder associated with the use of antipsychotic medications. Many of its classic signs, such as fever and altered mental status, are nonspecific in trauma intensive care unit (ICU) patients, and its rarity makes it a difficult diagnosis in this population. However, delays in treatment can be costly both in terms of hospital resources and patient outcomes. We herein report a case of a 54-year-old trauma patient with NMS precipitated by a combination of cocaine withdrawal and neuroleptic medications. Few cases of NMS in the intubated polytrauma patient have been described in the literature previously. Given the poor outcomes associated with this disorder, ICU patients would benefit from risk stratification and avoidance of neuroleptic medications in those at highest risk for NMS, particularly patients who are withdrawing from dopaminergic agents.

Citing Articles

Management of a trauma patient with alcohol withdrawal who developed neuroleptic malignant syndrome in Korea: a case report.

Yu B, Lee J, Kim Y, Park H, Jung J, Jo Y J Trauma Inj. 2024; 36(3):249-252.

PMID: 39381710 PMC: 11309282. DOI: 10.20408/jti.2022.0048.


Development of Atypical Neuroleptic Malignant Syndrome After Treatment of Cocaine Intoxication: A Case Report and Literature Review.

Miller M, Zezetko A, Satodiya R Cureus. 2023; 15(2):e35538.

PMID: 37007397 PMC: 10058510. DOI: 10.7759/cureus.35538.


Emergent Treatment of Neuroleptic Malignant Syndrome Induced by Antipsychotic Monotherapy Using Dantrolene.

Ngo V, Guerrero A, Lanum D, Burgett-Moreno M, Fenati G, Barr S Clin Pract Cases Emerg Med. 2019; 3(1):16-23.

PMID: 30775657 PMC: 6366389. DOI: 10.5811/cpcem.2018.11.39667.

References
1.
Shalev A, Hermesh H, Munitz H . Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989; 50(1):18-25. View

2.
Adnet P, Lestavel P, Krivosic-Horber R . Neuroleptic malignant syndrome. Br J Anaesth. 2000; 85(1):129-35. DOI: 10.1093/bja/85.1.129. View

3.
Levenson J . Neuroleptic malignant syndrome. Am J Psychiatry. 1985; 142(10):1137-45. DOI: 10.1176/ajp.142.10.1137. View

4.
Javed M, Bogdanov A . Oral dantrolene and severe respiratory failure in a patient with chronic spinal cord injury. Anaesthesia. 2010; 65(8):855-6. DOI: 10.1111/j.1365-2044.2010.06409.x. View

5.
Velamoor V . Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf. 1998; 19(1):73-82. DOI: 10.2165/00002018-199819010-00006. View